Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, females remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex differences across multiple...
Serotonergic psychedelics are advancing as psychiatric treatments, yet acute responses vary between individuals and the contribution of sex, a fundamental biological variable, remains largely unexamined. We pooled two double-blind, placebo-controlled studies in healthy volunteers (N = 72; 31 male, 41 female) comparing psilocybin 15 mg, 2C-B 20 mg, and LSD 50 μg. Linear mixed models tested sex...
Abstract Rationale: Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, women remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. Objectives This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex...
Psychedelic substances are increasingly recognized for their potential to catalyse transformative shifts in worldviews. Central to these transformations may be the integration of self-transcendent states. This mixed-methods study explored transformative psychedelic experiences, focussing on subsequent epistemic shifts. Ninety participants completed the Awe Experience Scale (AWE-S), and the...
Abstract Psychedelic substances are increasingly recognized for their potential to catalyse transformative shifts in worldviews. Central to these transformations are states of awe, a self-transcendent, epistemic emotion. This mixed-methods study explored how awe during psychedelic trips relates to lasting changes in boundaries between self and world, and epistemic shifts that follow...